secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0000950170-22-026739
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma elects James Flynn to Board; annual meeting results
------------------------------------------------------------------

- James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.
- Flynn granted option to purchase 12,000 shares at $2.32; other directors each granted 6,000-share options.
- Stockholders elected Grais, Hove, Flynn; ratified KPMG as auditor; approved executive compensation.
- Board is evaluating strategic options for the company, per press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/abio-20221215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer